No Laughing Matter: Nitrous Oxide and Depression

. 2025 Jun 13;5(5):100551.

doi: 10.1016/j.bpsgos.2025.100551. eCollection 2025 Sep.

Ella Williams¹, Philip J Cowen^{1

2}

Affiliations

¹ Department of Psychiatry, Oxford University, Warneford Hospital, Oxford, United Kingdom.
² Oxford Health National Health Service (NHS) Foundation Trust, Warneford Hospital, Oxford, United Kingdom.

Ella Williams et al. Biol Psychiatry Glob Open Sci. 2025.

. 2025 Jun 13;5(5):100551.

doi: 10.1016/j.bpsgos.2025.100551. eCollection 2025 Sep.

Ella Williams¹, Philip J Cowen^{1

2}

¹ Department of Psychiatry, Oxford University, Warneford Hospital, Oxford, United Kingdom.
² Oxford Health National Health Service (NHS) Foundation Trust, Warneford Hospital, Oxford, United Kingdom.

No abstract available

References

1. Jevtović-Todorović V., Todorović S.M., Mennerick S., Powell S., Dikranian K., Benshoff N., et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460–463. - PubMed
1. McIntyre R.S., Rosenblat J.D., Nemeroff C.B., Sanacora G., Murrough J.W., Berk M., et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383–399. - PMC - PubMed
1. Nagele P., Duma A., Kopec M., Gebara M.A., Parsoei A., Walker M., et al. Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial. Biol Psychiatry. 2015;78:10–18. - PubMed
1. Nagele P., Palanca B.J., Gott B., Brown F., Barnes L., Nguyen T., et al. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med. 2021;13 - PubMed
1. Myles P.S., Kulkarni J., Kasza J., Wallace S., Deng C., Turbić A., et al. Antidepressant effects of nitrous oxide in major depressive disorder: A phase 2b randomized clinical trial. Biol Psychiatry Glob Open Sci. 2025;5 - PMC - PubMed